Transpek Industry Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹716 Cr
- P/E
- 18.35
- ROE
- 6.14%
- PEG
- -1.00
- Price to sales
- 1.16
- Debt to equity
- 0.10
- 52W high / low
- ₹1,446 / ₹5.63
- Sales growth (5Y)
- 12.85%
- EBITDA margin
- 14.48%
- Net profit margin
- 7.48%
- Promoter holding
- 57.28%
- Sales (last year)
- ₹618 Cr
Incorporated in 1965, Transpek Industry Ltd manufactures and exports a range of chemicals[1]
Guidance scorecard · Q1 FY27 call
What Transpek Industry's management guided
and where it ranks in Chemicals & Petrochemicals
Chemicals & Petrochemicals
RevenueQ1 FY27 call
10–20%- Transpek Industry Limited expects a revenue growth of 15% to 20% for the current financial year (FY27) compared to the previous year.
- Growth is driven by volume plus value increase, with some products like acid chlorides already showing higher revenue (INR4 crores last year to an expected INR15 crores this year).
- The company plans to double its size and business in the next 5 years based on finalized strategies focusing on core product profiles and applications.
- New product commercialization is anticipated with two products expected to bring around INR50 crores each annually once fully commercialized.
- Some capex is planned ahead of confirmed demand based on market studies and customer relationships to support growth.
2 more points from Transpek Industry's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Transpek Industry said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Planned capex of around INR 250 crores over 5-6 years, phased.
- Odisha greenfield project: Board approval sought within 25-30 days; feasibility study filing and government presentations expected by Sept-Nov 2026.
- Project timelines: 3-4 months for permissions post-approval, with 1-2 years for construction and commercial production.
- Multi-purpose pilot plant at Ekalbara (not Odisha) to scale-up products from kilo-lab to tonnage, expected operational by Feb 2027.
- Continued investment in new product development; aiming for commercialization of several products generating INR 50-100 crores annually.
- Past capex (~INR 200 crores last 5-6 years) largely maintenance and captive consumption expansions, not growth-focused.
2 more points from Transpek Industry's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Transpek Industry said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- Bimal Mehta highlights that some customers are currently working with Transpek, providing clear visibility of demand for certain products.
- Discussions with customers for new contracts, including sizeable contracts similar to DuPont, are ongoing but delayed due to market volatility and cautious decision-making.
- Transpek has shifted from a very conservative capex approach to investing ahead of confirmed demand based on market studies and customer relationships.
- New products are under development, with expected revenue streams emerging by the end of the current financial year and the next year.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Chemicals & Petrochemicals companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹1,878 Cr | 21.0 | |
| 2 | 40%+ | Up 0–2% | ₹243 Cr | 3.1 | |
| 3 | 40%+ | Flat | ₹7,887 Cr | 195.1 | |
| 4 | 40%+ | Flat | ₹3,292 Cr | 4.3 | |
| 5 | 40%+ | Flat | ₹2,311 Cr | 26.4 | |
| 6 | 40%+ | Flat | ₹180 Cr | 11.8 |
Sign up free to see every company in the sector ranking and track Transpek Industry.
Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals rankingFinancials of Transpek Industry
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Transpek Industry
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 202.76 | 162.16 | 120.94 | 148.32 | 148.21 | 151.86 | 162.70 | 170.04 | 165.26 | 154.23 | 160.27 | 158.48 | 148.22 |
| Expenses + | 162.62 | 139.65 | 107.58 | 120.64 | 129.44 | 135.84 | 140.18 | 146.10 | 133.05 | 130.18 | 133.59 | 133.55 | 130.49 |
| Operating Profit | 40.14 | 22.51 | 13.36 | 27.68 | 18.77 | 16.02 | 22.52 | 23.94 | 32.21 | 24.05 | 26.68 | 24.93 | 17.73 |
| OPM % | 19.80% | 13.88% | 11.05% | 18.66% | 12.66% | 10.55% | 13.84% | 14.08% | 19.49% | 15.59% | 16.65% | 15.73% | 11.96% |
| Other Income + | 5.29 | 11.67 | 4.07 | 4.63 | 4.79 | 10.98 | 5.09 | 4.89 | 7.74 | 11.66 | 5.03 | 3.54 | 4.27 |
| Interest | 5.79 | 4.15 | 3.04 | 3.69 | 3.49 | 3.01 | 2.82 | 3.12 | 2.79 | 2.46 | 2.41 | 1.67 | 1.52 |
| Depreciation | 8.49 | 8.78 | 8.83 | 8.66 | 11.33 | 12.32 | 12.89 | 12.13 | 12.64 | 12.32 | 12.34 | 12.34 | 11.64 |
| Profit before tax | 31.15 | 21.25 | 5.56 | 19.96 | 8.74 | 11.67 | 11.90 | 13.58 | 24.52 | 20.93 | 16.96 | 14.46 | 8.84 |
| Tax % | 28.19% | 25.41% | 46.22% | 29.46% | 35.47% | 20.31% | 19.66% | 21.58% | 21.49% | 25.56% | 25.53% | 25.03% | 25.45% |
| Net Profit + | 22.37 | 15.85 | 2.99 | 14.08 | 5.64 | 9.29 | 9.55 | 10.65 | 19.25 | 15.58 | 12.64 | 10.85 | 6.58 |
| EPS in Rs | 40.05 | 28.38 | 5.35 | 25.21 | 10.10 | 16.63 | 17.10 | 19.07 | 34.46 | 27.89 | 22.63 | 19.42 | 11.78 |
Financials of Transpek Industry
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 290 | 284 | 317 | 361 | 595 | 566 | 339 | 599 | 827 | 580 | 650 | 621 |
| Expenses + | 251 | 236 | 263 | 314 | 478 | 447 | 292 | 499 | 676 | 497 | 547 | 528 |
| Operating Profit | 38 | 48 | 53 | 47 | 117 | 118 | 47 | 100 | 151 | 82 | 103 | 93 |
| OPM % | 13% | 17% | 17% | 13% | 20% | 21% | 14% | 17% | 18% | 14% | 16% | 15% |
| Other Income + | 11 | 2 | 7 | 10 | 18 | 17 | 17 | 24 | 14 | 25 | 20 | 24 |
| Interest | 13 | 11 | 9 | 12 | 19 | 16 | 10 | 11 | 19 | 14 | 12 | 8 |
| Depreciation | 9 | 8 | 9 | 10 | 14 | 26 | 29 | 30 | 33 | 38 | 50 | 49 |
| Profit before tax | 27 | 32 | 42 | 35 | 101 | 94 | 26 | 84 | 113 | 56 | 62 | 61 |
| Tax % | 18% | 33% | 29% | 25% | 35% | 22% | 9% | 22% | 26% | 31% | 21% | 25% |
| Net Profit + | 22 | 21 | 30 | 26 | 66 | 73 | 23 | 65 | 83 | 39 | 49 | 46 |
| EPS in Rs | 37.41 | 36.24 | 53.67 | 47.26 | 117.70 | 130.59 | 41.73 | 117.09 | 149.46 | 69.03 | 87.26 | 81.73 |
| Dividend Payout % | 13% | 21% | 17% | 19% | 17% | 10% | 18% | 19% | 18% | 20% | 23% | 24% |
Financials of Transpek Industry
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 69 | 85 | 200 | 241 | 306 | 333 | 374 | 479 | 581 | 668 | 740 | 762 |
| Borrowings + | 77 | 64 | 88 | 203 | 144 | 116 | 111 | 137 | 145 | 123 | 94 | 60 |
| Other Liabilities + | 77 | 55 | 93 | 116 | 143 | 134 | 109 | 143 | 155 | 169 | 161 | 181 |
| Total Liabilities | 229 | 209 | 386 | 566 | 599 | 589 | 599 | 764 | 887 | 966 | 1,001 | 1,008 |
| Fixed Assets + | 92 | 94 | 117 | 179 | 236 | 287 | 287 | 295 | 365 | 397 | 360 | 343 |
| CWIP | 5 | 10 | 13 | 56 | 33 | 19 | 14 | 16 | 24 | 6 | 5 | 5 |
| Investments | 5 | 5 | 131 | 144 | 149 | 118 | 142 | 196 | 238 | 321 | 328 | 316 |
| Other Assets + | 126 | 100 | 125 | 188 | 180 | 166 | 156 | 258 | 260 | 242 | 307 | 344 |
| Total Assets | 229 | 209 | 386 | 566 | 599 | 589 | 599 | 764 | 887 | 966 | 1,001 | 1,008 |
Financials of Transpek Industry
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 44 | 47 | 7 | 128 | 111 | 35 | 47 | 111 | 98 | 135 | |
| Cash from Investing Activity + | 14 | -16 | -31 | -103 | -45 | -33 | -17 | -70 | -13 | -32 | -30 | |
| Cash from Financing Activity + | -33 | -27 | -17 | 96 | -83 | -77 | -3 | 9 | -94 | -64 | -56 | |
| Net Cash Flow | -0 | 1 | -1 | 0 | -0 | 0 | 15 | -14 | 4 | 3 | 48 | |
| Free Cash Flow | 24 | 27 | 10 | -112 | 80 | 74 | 20 | 9 | 66 | 60 | 116 | |
| CFO/OP | 52% | 103% | 106% | 38% | 126% | 114% | 81% | 70% | 97% | 133% | 140% |
Financials of Transpek Industry
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 103 | 59 | 78 | 94 | 57 | 58 | 82 | 60 | 52 | 58 | 58 | 88 |
| Inventory Days | 68 | 111 | 91 | 87 | 68 | 70 | 82 | 77 | 54 | 82 | 74 | 63 |
| Days Payable | 114 | 60 | 83 | 103 | 72 | 73 | 81 | 65 | 45 | 58 | 70 | 87 |
| Cash Conversion Cycle | 57 | 110 | 85 | 78 | 54 | 54 | 83 | 72 | 61 | 81 | 61 | 64 |
| Working Capital Days | 11 | 22 | 10 | -8 | 11 | 60 | 27 | 17 | 32 | 44 | 44 | 52 |
| ROCE % | 22% | 28% | 23% | 13% | 27% | 24% | 7% | 18% | 20% | 9% | 10% | 8% |
Guidance history
How Transpek Industry's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY25 call → | 0–10% | Flat | Planned | — | — |
| Q4 FY24 call → | 10–20% | Flat | None planned | None planned | — |
| Q3 FY23 call → | 20–40% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
29 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,928 stocks |
|---|---|---|
| Last 12 months | −8.7% | 45% |
| Last 6 months | +7.2% | 62% |
| Last 3 months | +4.9% | 73% |
The price is 47% below its all-time high of ₹2,440.3 (4 Nov 2021). Stocks more than 20% below their peak have their score halved, so 57 became 29.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,928 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Transpek Industry: 0.4 × 45 + 0.4 × 62 + 0.2 × 73 = 57, halved to 29 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 9 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Transpek Industry's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Unilex Colour &C (Q2 FY27)
685.02 lakhs (Consolidated) with a YoY increase of approximately 2.22% (Rs. Key results statement takeaways from Unilex Colour & Chemical Ltd's Q2 FY27 results
- Andhra Sugars (Q2 FY27)
3,276.52 lakhs (~5.5% increase) . Key results statement takeaways from Andhra Sugars Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Shanti Inorganics (Q2 FY27)
54.02 crore (Rs. Key results statement takeaways from Shanti Inorganics Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Prolife Industries (Q2 FY27)
Year-on-Year Change for PAT**: Specific YoY % change not provided; previous period PAT for the half year ended Sept 30, 2025 is not provided in the shared…
